TrialSignal
Clinical trial intelligence report
An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05565248
Status
TERMINATED
Phase
Phase 1
Sponsor
CRISPR Therapeutics AG
Executive brief
Investment-Ready Snapshot
CRISPR Therapeutics AG is advancing VCTX211, a combination product aimed at treating Type 1 Diabetes Mellitus (T1D) through innovative gene editing technology. The asset is positioned in a competitive landscape that includes traditional insulin therapies and emerging cell therapies. The termination of this trial suggests a strategic pivot towards the VCTX-201 study, indicating a focus on refining the approach or addressing challenges encountered in the initial trial. The T1D market is substantial, with increasing demand for novel therapies that enhance patient outcomes and reduce complications associated with the disease. The collaboration with ViaCyte may enhance the development and commercialization potential of VCTX211, leveraging their expertise in cell therapy.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05565248
Indication
Diabetes Mellitus
Modality
gene therapy
Target
Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
Intervention
VCTX211
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.